title: Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users.
abstract: Human immunodeficiency virus (HIV)-infected, active intravenous drug users received once-daily therapy consisting of a combination of didanosine (2',3'-dideoxyinosine or DDI), lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine or 3TC] and nevirapine. Preliminary results for the first 24 weeks show that the regimen provides potent immunological and antiviral effects.
authors.affiliation: Klinikum der JW Goethe-Universität Frankfurt, Zentrum der Inneren Medizin, Germany. staszewski@em.uni-frankfurt.de
authors.forename: S
authors.initials: S
authors.lastname: Staszewski
authors.forename: A
authors.initials: A
authors.lastname: Haberl
authors.forename: P
authors.initials: P
authors.lastname: Gute
authors.forename: G
authors.initials: G
authors.lastname: Nisius
authors.forename: V
authors.initials: V
authors.lastname: Miller
authors.forename: A
authors.initials: A
authors.lastname: Carlebach
mesh_terms: D000328:Adult; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D008297:Male; D008691:Methadone / Q000627:therapeutic use; D019829:Nevirapine / Q000008:administration & dosage*; D010865:Pilot Projects; D011446:Prospective Studies; D015819:Substance Abuse, Intravenous / Q000150:complications* / Q000188:drug therapy; D019562:Viral Load
chemical_list: D019259:Lamivudine; D019829:Nevirapine; D016049:Didanosine; D008691:Methadone